Background: Multiple Sclerosis (MS) is a growing global health challenge affecting nearly 3
million people. Progress has been made in the understanding and treatment of MS over the …

The modern treatment era for multiple sclerosis (MS) began in 1993 with the approval of the
first disease-modifying agent. Since then the field has greatly expanded, with 10 therapies …

Emerging data point to important contributions of both autoimmune inflammation and
progressive degeneration in the pathophysiology of multiple sclerosis (MS). Unfortunately …

Multiple sclerosis (MS) has been thought to be a complex and indecipherable disease, and
poorly understood with regards to aetiology. Here, we suggest an emphatically positive view …

Multiple sclerosis: clinical trial design 2019 : Current Opinion in Neurology Multiple sclerosis:
clinical trial design 2019 : Current Opinion in Neurology Log in or Register Subscribe to …

Current therapeutic landscape in multiple sclerosis: an evol... : Current Opinion in
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …

Multiple sclerosis is a chronic and often disabling disease of the nervous system, affecting
about 1 million people worldwide. Even though it has been known for over a hundred years …

Identifying effective therapies for the treatment of progressive forms of multiple sclerosis
(MS) is a highly relevant priority and one of the greatest challenges for the global MS …

In 2017, extensive research into multiple sclerosis (MS) resulted in improved diagnostic
criteria, development of biomarkers that enable monitoring of disease evolution and …

In a rapidly evolving treatment landscape for multiple sclerosis (MS), the utilization of real-
world observational studies has become increasingly valuable for decisionmaking at the …